Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
A
Deeply overvalued
AGILENT TECHNOLOGIES, INC.
Price$168.17
Model IV$75.29
P/IV2.22
Premium +123%
Return to IV: -55.2%
Market implies +17.2%/yr
vs model +7.7% · above model
ALMR
Valuation N/A
Alamar Biosciences, Inc.
Price$25.91
Model IV—
P/IV—
Limited data — see page
ASTC
Valuation N/A
ASTROTECH Corp
Price$6.84
Model IV—
P/IV—
Market implies +41.5%/yr
AVTR
Overvalued
Avantor, Inc.
Price$15.39
Model IV$11.92
P/IV1.29
Premium +29%
Return to IV: -22.5%
Market implies +8.5%/yr
vs model +6.1% · in line
BIO
Deeply overvalued
BIO-RAD LABORATORIES, INC.
Price$360.40
Model IV$255.42
P/IV1.45
Premium +41%
Return to IV: -29.1%
Market implies +9.5%/yr
vs model +6.1% · above model
BNGO
Deeply undervalued
Bionano Genomics, Inc.
Price$1.46
Model IV$3.09
P/IV0.47
Discount 53%
Return to IV: +111.6%
Market implies -15.6%/yr
vs model +12.2% · below model
BRKR
Deeply overvalued
BRUKER CORP
Price$57.92
Model IV$43.47
P/IV1.39
Premium +33%
Return to IV: -24.9%
Market implies +2.5%/yr
vs model +9.2% · below model
BRKRP
Valuation N/A
BRUKER CORP
Price$427.67
Model IV—
P/IV—
Market implies +27.9%/yr
CTKB
Deeply overvalued
Cytek Biosciences, Inc.
Price$5.36
Model IV$1.73
P/IV2.42
Premium +210%
Return to IV: -67.7%
Market implies +14.6%/yr
vs model +12.0% · in line
EYPT
Valuation N/A
EyePoint, Inc.
Price$3.46
Model IV—
P/IV—
Limited data — see page
HBIO
Valuation N/A
HARVARD BIOSCIENCE INC
Price$8.13
Model IV—
P/IV—
Market implies +37.2%/yr
vs model +2.0% · above model
ILMN
Deeply overvalued
ILLUMINA, INC.
Price$264.57
Model IV$80.21
P/IV3.18
Premium +230%
Return to IV: -69.7%
Market implies +21.4%/yr
vs model +6.6% · above model
LAB
Valuation N/A
STANDARD BIOTOOLS INC.
Price$0.67
Model IV—
P/IV—
Market implies +35.9%/yr
vs model +2.0% · above model
MTD
Deeply overvalued
METTLER TOLEDO INTERNATIONAL INC/
Price$1,529.46
Model IV$792.57
P/IV1.49
Premium +93%
Return to IV: -48.2%
Market implies +15.1%/yr
vs model +7.5% · above model
NAUT
Valuation N/A
Nautilus Biotechnology, Inc.
Price$1.82
Model IV—
P/IV—
Limited data — see page
PACB
Valuation N/A
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Price$2.30
Model IV—
P/IV—
Market implies +50.0%/yr
vs model +5.2% · above model
PRE
Valuation N/A
Prenetics Global Ltd
Price$22.00
Model IV—
P/IV—
Limited data — see page
PRENW
Valuation N/A
Prenetics Global Ltd
Price$0.01
Model IV—
P/IV—
Limited data — see page
PRPO
Undervalued
Precipio, Inc.
Price$23.19
Model IV$31.03
P/IV0.77
Discount 25%
Return to IV: +33.8%
Market implies -7.3%/yr
vs model +28.4% · below model
QTRX
Deeply overvalued
Quanterix Corp
Price$3.21
Model IV$1.33
P/IV2.38
Premium +142%
Return to IV: -58.7%
Market implies +12.5%/yr
vs model +5.9% · above model
RPID
Deeply overvalued
RAPID MICRO BIOSYSTEMS, INC.
Price$0.86
Model IV$0.38
P/IV2.90
Premium +125%
Return to IV: -55.6%
Market implies +9.0%/yr
vs model +9.7% · in line
RVTY
Deeply overvalued
REVVITY, INC.
Price$152.16
Model IV$43.09
P/IV2.43
Premium +253%
Return to IV: -71.7%
Market implies +19.9%/yr
vs model +2.0% · above model
SEER
Deeply overvalued
Seer, Inc.
Price$2.17
Model IV$0.65
P/IV2.79
Premium +236%
Return to IV: -70.2%
Market implies +13.0%/yr
vs model +25.8% · below model
TXG
Valuation N/A
10x Genomics, Inc.
Price$77.28
Model IV—
P/IV—
Market implies +33.5%/yr
WAT
Deeply overvalued
WATERS CORP /DE/
Price$429.13
Model IV$179.44
P/IV2.34
Premium +139%
Return to IV: -58.2%
Market implies +18.2%/yr
vs model +8.0% · above model